ストックスクリーナーアプリを入手
41.23
4.78%
1.88
前日終値:
$39.35
開ける：
$39.87
24時間の取引高:
727.01K
Relative Volume:
0.69
時価総額：
$2.29B
収益：
$249.12M
当期純損益:
$-90.19M
株価収益率:
-24.25
EPS:
-1.7
ネットキャッシュフロー:
$-88.21M
1週間 パフォーマンス:
-0.87%
1か月 パフォーマンス:
-29.83%
6か月 パフォーマンス:
-33.77%
1年 パフォーマンス:
-48.64%
1日の値動き範囲:
$39.27
$41.42
1週間の範囲:
$38.67
$42.19
52週間の値動き範囲:
$37.12
$103.81
Procept Biorobotics Corp Stock (PRCT) Company Profile
PRCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRCT
Procept Biorobotics Corp
|
41.23 | 2.26B | 249.12M | -90.19M | -88.21M | -1.70 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Procept Biorobotics Corp Stock (PRCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-09 | 開始されました | Stephens | Overweight |
| 2025-07-07 | 開始されました | Oppenheimer | Perform |
| 2024-12-02 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | 開始されました | Jefferies | Hold |
| 2023-08-11 | 開始されました | Piper Sandler | Overweight |
| 2023-05-31 | 開始されました | William Blair | Outperform |
| 2022-10-31 | 開始されました | BTIG Research | Neutral |
| 2022-10-25 | 開始されました | Truist | Buy |
| 2022-09-02 | 開始されました | Wells Fargo | Overweight |
| 2022-07-15 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2022-06-23 | 開始されました | B. Riley Securities | Buy |
| 2021-10-11 | 開始されました | BofA Securities | Buy |
| 2021-10-11 | 開始されました | Cowen | Outperform |
| 2021-10-11 | 開始されました | Goldman | Neutral |
| 2021-10-11 | 開始されました | Guggenheim | Buy |
| 2021-10-11 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Procept Biorobotics Corp (PRCT) 最新ニュース
PROCEPT BioRobotics Corporation Attempts Reversal From Key SupportJuly 2025 Update & Fast Entry and Exit Trade Plans - classian.co.kr
PROCEPT BioRobotics Independent Director Acquires 2.4% More Stock - 富途牛牛
Overvalued Healthcare Tech Stocks: How Predictive Models Can Anticipate Market Corrections—A Case Study of PROCEPT BioRobotics (PRCT) - AInvest
Why PROCEPT BioRobotics (PRCT) Is Up 8.3% After Raising 2025 Revenue Guidance - simplywall.st
PROCEPT BioRobotics Corporation Shows Risk Reward Favoring Upside2025 Year in Review & Accurate Entry and Exit Point Alerts - 선데이타임즈
Why PROCEPT BioRobotics Corporation stock attracts strong analyst attentionAnalyst Upgrade & Entry and Exit Point Strategies - sundaytimes.kr
Director’s Bold Move: Major Investment in PROCEPT BioRobotics - TipRanks
Procept BioRobotics: A High-Growth Buy with Strengthening Pricing Power and Global Expansion Momentum - AInvest
Procept BioRobotics: Boosting Average Selling Price, Initiates Buy Rating - AInvest
Procept BioRobotics: Increasing Average Selling Price, Initiate At Buy (NASDAQ:PRCT) - Seeking Alpha
PROCEPT BioRobotics 15min chart: RSI Oversold, KDJ Golden Cross detected. - AInvest
Leerink Partners Reiterates a Buy Rating on PROCEPT BioRobotics (PRCT) - MSN
PROCEPT BioRobotics (PRCT) Guides Higher on Q2 Revenue Beat and Narrowing Losses – What Signals Ahead? - simplywall.st
Procept BioRobotics Grows Fast Despite Wall Street Skepticism - Finimize
PROCEPT BioRobotics Reports Strong Q2 2025 Growth - TipRanks
Why PROCEPT BioRobotics Shares Are Tumbling - TipRanks
Procept Biorobotics Reports Strong Q2 Growth Amid Challenges - TipRanks
PROCEPT BioRobotics outlines $325.5M 2025 revenue target amid leadership transition and margin expansion - MSN
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q2 2025 Earnings Call Transcript - MSN
What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S After Its 34% Share Price Crash - simplywall.st
Procept Biorobotics Corp.’s Aquablation Therapy: A Promising Update for Prostate Cancer Treatment - The Globe and Mail
Edwards’ Longtime TAVR Leader is Named PROCEPT BioRobotics CEO - Medical Product Outsourcing
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $55 to $83 - 富途牛牛
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$65.75 Price Target - simplywall.st
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Qiagen (QGEN) - The Globe and Mail
PROCEPT BioRobotics 2025 Q2 Earnings Improved Losses Amid Revenue Surge - AInvest
PROCEPT BioRobotics Posts Q2 2025 Earnings: Revenue Up 48%, Net Loss Narrows by 24% - AInvest
PROCEPT BioRobotics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Buy Rating for PROCEPT BioRobotics: Growth Potential and Stability Amid Sales Beat and Improved Guidance - TipRanks
Procept BioRobotics' Q2 Revenue Jumps 48%, Exceeds Estimates - AInvest
PROCEPT BioRobotics Reports 48% YoY Revenue Growth in Q2 2025 - AInvest
Procept Biorobotics shares fall 13.46% intraday despite increased revenue guidance for 2025. - AInvest
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $85 to $85 - 富途牛牛
Earnings call transcript: Procept BioRobotics Q2 2025 beats forecasts, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Procept BioRobotics Q2 2025 beats forecasts, stock dips - Investing.com
Truist Lowers Price Target on PROCEPT BioRobotics to $64 From $70, Keeps Buy Rating - MarketScreener
Wells Fargo lowers Procept BioRobotics stock price target on delayed system replacements - Investing.com Canada
Optimistic Outlook on PROCEPT BioRobotics Amidst Medtech Sector Challenges - TipRanks
PROCEPT BioRobotics (PRCT): Assessing the Path to Profitability Amid Leadership Transition and Global Expansion - AInvest
PROCEPT BioRobotics Sets $325.5M 2025 Revenue Target Amid Leadership Change and Margin Expansion - AInvest
Transcript : PROCEPT BioRobotics Corporation, Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Procept (PRCT) Q2 Revenue Jumps 48% - The Globe and Mail
Procept (PRCT) Q2 Revenue Jumps 48% - The Motley Fool
PROCEPT BioRobotics (PRCT) Earnings Transcript - Mitrade
Procept Biorobotics shares fall 3.72% after-hours despite Q2 revenue up 48% and raised 2025 guidance. - AInvest
Procept Biorobotics earnings beat by $0.06, revenue topped estimates - Investing.com South Africa
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Zimmer Biomet (ZBH) Q2 Revenue Jumps 7% - AOL.com
PROCEPT BioRobotics Q2 revenue up 48% YoY to $79.2mln. - AInvest
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results - TradingView
Procept Biorobotics Corp (PRCT) 財務データ
収益
当期純利益
現金流量
EPS
Procept Biorobotics Corp (PRCT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MOLL FREDERIC H | Director |
Aug 13 '25 |
Buy |
39.26 |
20,000 |
785,138 |
863,159 |
| Nouri Alaleh | EVP, CLO, CORP. SEC. |
Aug 14 '25 |
Option Exercise |
4.52 |
11,000 |
49,720 |
72,473 |
| Desai Antal Rohit | Director |
Jun 10 '25 |
Sale |
63.91 |
25,000 |
1,597,711 |
64,363 |
| Desai Antal Rohit | Director |
Jun 11 '25 |
Sale |
63.38 |
25,000 |
1,584,525 |
39,363 |
| Desai Antal Rohit | Director |
Jun 12 '25 |
Sale |
61.49 |
25,000 |
1,537,256 |
14,363 |
0.89%
大文字化:
|
ボリューム (24 時間):